Skip to Content

Oncology Pharma Inc ONPH

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Oncology Pharma Inc is an oncology company. It is engaged in the development, manufacturing, and commercialization of therapeutics. Its NanoSmart's platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. The company has developed a novel drug delivery vehicle that targets many types of cancer.

Contact
One Sansome Street, Suite 305, PMB No. 100517
San Francisco, CA, 94104
T +1 415 869-1038
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2004
Fiscal Year End Mar 31, 2021
Stock Type Distressed
Employees 18